Iranian Red Crescent Medical Journal

Published by: Kowsar

A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection

Seyed Moayed Alavian 1 , Shekoufeh Nikfar 2 , Abbas Kebriaeezadeh 2 , Farhad Lotfi 3 , Ehsan Sanati 2 , Mohsen Rezaei Hemami 4 and Khosro Keshavarz 3 , *
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
3 Health Human Resource Research Center, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Institute of Health and Wellbeing, Health Economics and Health Technology Assessment, University of Glasgow
Article information
  • Iranian Red Crescent Medical Journal: November 01, 2016, 18 (11); e37094
  • Published Online: October 2, 2016
  • Article Type: Research Article
  • Received: February 13, 2016
  • Revised: June 5, 2016
  • Accepted: August 14, 2016
  • DOI: 10.5812/ircmj.37094

To Cite: Alavian S M, Nikfar S, Kebriaeezadeh A, Lotfi F, Sanati E, et al. A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection, Iran Red Crescent Med J. 2016 ; 18(11):e37094. doi: 10.5812/ircmj.37094.

Abstract
Copyright © 2016, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in IR IRAN. Gastroenterology and Hepatology from bed to bench. 2009; 3(1)
  • 2. Gordon SC, Hamzeh FM, Pockros PJ, Hoop RS, Buikema AR, Korner EJ, et al. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther. 2013; 38(7): 784-93[DOI][PubMed]
  • 3. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24): 2584-93[DOI][PubMed]
  • 4. D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012; 56(2): 532-43[DOI][PubMed]
  • 5. Ashtari S, Vahedi M, Pourhoseingholi MA, Karkhane M, Kimiia Z, Pourhoseingholi A, et al. Direct medical care costs associated with patients diagnosed with chronic HCV. Hepat Mon. 2013; 13(5): 8415[DOI][PubMed]
  • 6. Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon. 2014; 14(11): 25540[DOI][PubMed]
  • 7. Liang TJ, Ghany MG. Therapy of hepatitis C--back to the future. N Engl J Med. 2014; 370(21): 2043-7[DOI][PubMed]
  • 8. Sheridan C. FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol. 2014; 32(1): 3-5[DOI][PubMed]
  • 9. Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther. 2014; 95(1): 78-88[DOI][PubMed]
  • 10. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370(20): 1889-98[DOI][PubMed]
  • 11. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370(20): 1879-88[DOI][PubMed]
  • 12. Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, et al. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010; 54(8): 3187-96[DOI][PubMed]
  • 13. Keyvani H, Alizadeh AH, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res. 2007; 37(2): 101-3[DOI][PubMed]
  • 14. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015; 41(6): 544-63[DOI][PubMed]
  • 15. Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014; 40(6): 657-75[DOI][PubMed]
  • 16. Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2014; 59(5): 1692-705[DOI][PubMed]
  • 17. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014; 60(1): 37-45[DOI][PubMed]
  • 18. Abdoli G. Estimation of social discount rate for Iran. Eco Res Rev. 2009; 10(3): 135-56
  • 19. Robberstad B. Estimation of private and social time preferences for health in northern Tanzania. Soc Sci Med. 2005; 61(7): 1597-607[DOI][PubMed]
  • 20. Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. Daru. 2013; 21(1): 50[DOI][PubMed]
  • 21. Alavian SM, Hajarizadeh B, Hajibeigi B, Doroudi T, Hamadanizadeh AK, Abar K. Efficacy and safety of pegylated interferon alfa-2a plus ribavirin for treatment of chronic hepatitis C and cirrhosis in Iranian. Hepat Mon. 2004; 4(7): 53-8
  • 22. Aval F, Behnaz N, Raoufy M, Alavian SM. Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepat mon. 2014; 14(6)
  • 23. Alavian SM. Sofosbuvir has come out of the magic box. Hepat mon. 2013; 13(12)
  • 24. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381(9883): 2100-7[DOI][PubMed]
  • 25. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48(2): 418-31[DOI][PubMed]
  • 26. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011; 54(2): 396-405[DOI][PubMed]
  • 27. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Annals Inter Med. 2013; 158(5_Part_1): 329-37
  • 28. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. Hepatol. 1997; 27(1): 201-5
  • 29. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997; 127(10): 855-65[PubMed]
  • 30. Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. Eur J Gastroenterol Hepatol. 2012; 24(2): 186-94[DOI][PubMed]
  • 31. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013; 57(6): 2164-70[DOI][PubMed]
  • 32. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008; 135(3): 821-9[DOI][PubMed]
  • 33. Butler J, Korda RJ, Watson KJ, Watson AR. The impact of chronic hepatitis B in Australia: Projecting mortality, morbidity and economic impact. Canberra: Australian Centre for Economic Research on Health. 2009;
  • 34. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012; 156(4): 279-90[DOI][PubMed]
  • 35. PPP conversion factor, Private consumption.
  • 36. Elliott R, Payne K. Essentials of economic evaluation in healthcare. 2005;
  • 37. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics. 2009; 27(11): 903-17[DOI][PubMed]
  • 38. Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res. 2014; 14: 170[DOI][PubMed]
  • 39. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2014; 60(3): 530-7[DOI][PubMed]
  • 40. Dugum M, O'Shea R. Hepatitis C virus: here comes all-oral treatment. Cleve Clin J Med. 2014; 81(3): 159-72[DOI][PubMed]
  • 41. Asselah T, Marcellin P. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver Int. 2014; 34 Suppl 1: 60-8[DOI][PubMed]
  • 42. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clinical Gastroenterol Hepatol. 2014; 12(8): 1349-59
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments